Product – Exo-PTEN

Product - ExoPTEN

ExoTherapy-based product targeted at the acute SCI market

Initial indications from a pre-clinical study have demonstrated the potential for an off-the-shelf therapy for non-invasive administration shortly after spinal cord trauma. The product, which would not require personalization, is expected to reduce damage from a spinal-cord injury and to improve the chance of functional recovery.

The aim is to be able to recover function after any acute or traumatic SCI. Introducing any level of recovery, partial or complete, would bring significant relief to the patient and direct improvement of their quality of life.

The table below summarizes the potential advantages of NurExone’s ExoTherapy. 

Product ExoPTEN Table-Correc

Set layout popup

ExoPTEN has been granted Orphan Drug Designation (“ODD”) by the FDA indicating the priority of developing therapies for acute SCI conditions. ODD is expected to streamline regulatory and clinical process